Close

Griffen Securities Positive on ZIOPHARM's (ZIOP) Latest Membrane-Bound IL-15 Data; Affirms at 'Buy'

Go back to Griffen Securities Positive on ZIOPHARM's (ZIOP) Latest Membrane-Bound IL-15 Data; Affirms at 'Buy'

Ziopharm Oncology (ZIOP) Announces Presentation of Ad-RTS-hIL-12 + Veledimex Data at 21st ASM of SNO

November 17, 2016 7:08 AM EST

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced the presentation of both clinical and nonclinical data for Ad-RTS-hIL-12 + orally-administered veledimex for recurrent brain cancer at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) held November 17-20, 2016 in Scottsdale, Arizona. Ad-RTS-hIL-12 + veledimex is a novel viral gene therapy candidate utilizing the proprietary RheoSwitch Therapeutic System® (RTS®) technology for the controlled expression of interleukin 12 (IL-12), a critical protein for stimulating a vigorous immune response against cancers.

In a poster presentation titled Phase 1 study of intra-tumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex is well... More